Company Overview and News

 
The Zacks Analyst Blog Highlights: Oshkosh, Allison Transmission, Fox Factory, Ferrari and Lear

2018-05-23 zacks
Chicago, IL – May 23, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Oshkosh Corp. (OSK - Free Report) , Allison Transmission Holdings, Inc. (ALSN - Free Report) , Fox Factory Holding Corp. (FOXF - Free Report) , Ferrari N.

 
5 Auto Stocks to Buy as China Reduces Import Tariffs on Cars

2018-05-22 zacks
On May 22, China decided to slash import tariffs on passenger cars and auto parts starting as early as on Jul 1. Following the easing of trade tensions with the United States, China’s latest move is definitely expected to drive up the U.S. auto market. In fact, as the biggest auto industry for foreign automakers, a tax relief on auto imports to China is a big positive for foreign automakers that have struggled to sell cars in China in recent times.

 
Tracking Lou Simpson's SQ Advisors Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
SQ Advisors has just fifteen positions. The top three holdings are Allison Transmission, Brookfield Asset Management, and Charles Schwab, and they add up to one-third of the entire portfolio.

 
Prius-Era Hybrid Pioneer Sees Long Road Toward Electric Big Rigs - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
ALSN / Allison Transmission Holdings, Inc. FORM 8-K (Current Report)

2018-05-15 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

 
ALSN / Allison Transmission Holdings, Inc. FORM 8-K (Current Report)

2018-05-11 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

 
Zacks.com featured highlights include: Kemper, WildHorse, Hi-Crush, Allison and Enova

2018-05-10 zacks
Chicago, IL – May 10, 2018 - Stocks in this week’s article Kemper Corp. (KMPR - Free Report) , WildHorse Resource Development Corp. (WRD - Free Report) , Hi-Crush Partners LP (HCLP - Free Report) , Allison Transmission Holdings Inc. (ALSN - Free Report) and Enova International, Inc. (ENVA - Free Report) .

 
Bet on 5 High-Flying Stocks with Relative Price Strength

2018-05-09 zacks
Earnings growth and valuation multiples are indeed important for investors to determine a stock's ability to offer considerable returns. But these are also essential in determining whether a stock’s price performance is better than its peers or the industry average.

 
Nissan Announces Gradual Removal of Diesel Cars From Europe

2018-05-08 zacks
Per Reuters, Nissan Motor Company (NSANY - Free Report) announced plan to gradually discontinue selling diesel passenger cars in Europe. Declining demand by customers, due to restrictions on diesel-enabled vehicles in many countries, has forced the company to take this decision. Further, rising focus on electrified options has also added to the decision.

 
Toyota (TM) Invests $1.1B to Boost RAV4 Production in Canada

2018-05-07 zacks
Per Bloomberg, Toyota Motor Corporation (TM - Free Report) announced an investment of $1.1 billion (C$1.4 billion) for the development of Canadian operations to manufacture usual and hybrid RAV4 sport utility vehicles (SUV). This development came amid the uncertainty over North American Free Trade Agreement (NAFTA) talks.

 
American Axle's (AXL) Q1 Earnings & Revenues Beat Estimates

2018-05-07 zacks
Shares of American Axle & Manufacturing Holdings, Inc. (AXL - Free Report) gained 4.6% in a day’s trading, following its first-quarter 2018 earnings release. The company posted adjusted earnings of 98 cents per share for first-quarter 2018, beating the Zacks Consensus Estimate of 81 cents. In first-quarter 2017, adjusted earnings were $1.03.

 
Meritor (MTOR) Q2 Earnings Beat Estimates, Guidance Upbeat

2018-05-04 zacks
Shares of Meritor, Inc. (MTOR - Free Report) gained roughly 1.9% in a day’s trading, following its second-quarter fiscal 2018 earnings release. The company recorded adjusted earnings of 75 cents per share in second-quarter fiscal 2018 (ended Mar 31, 2018) compared with 35 cents a year ago. The figure comfortably surpassed the Zacks Consensus Estimate of 65 cents.

1
ALSN / Allison Transmission Holdings, Inc. 10-Q (Quarterly Report)

2018-05-01 sec.gov
10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

 
Allison Transmission Holdings (ALSN) Q1 2018 Results - Earnings Call Transcript

2018-05-01 seekingalpha
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Allison Transmission's First Quarter 2018 Results Conference Call. My name is Melissa, and I will be your conference call operator today. At this time, all participants are in a listen-only mode. After the prepared remarks, the management from Allison Transmission will conduct a question-and-answer session and conference call participants will be given instructions at that time.

 
Johnson Controls (JCI) Q2 Earnings & Revenues Beat Estimates

2018-05-01 zacks
Johnson Controls International plc (JCI - Free Report) reported adjusted earnings of 53 cents per share in second-quarter fiscal 2018, beating the Zacks Consensus Estimate of 52 cents. Moreover, earnings increased 6% from 50 cents per share registered in second-quarter fiscal 2017. Operational Update Johnson Controls reported revenues of $7.48 billion, surpassing the Zacks Consensus Estimate of $7.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 01973R101